http://www.fpnotebook.com/
TekturnaAka: Aliskiren, Direct renin inhibitor
- Mechanism
- Direct renin inhibitor
- Full effect at current dose within 2 weeks of starting
- Additive effect on Hypertension when combined with other agents
- Addiditive effect in combination with ACE Inhibitors, Angiotensin Receptor Blockers
- Additive effect in combination with Diuretics
- Possible additive effect in combination with Amlodipine
- Pharmacokinetics
- Renally excreted (renal dose adjustment not necessary, but requires monitoring)
- Metabolized by CYP3A4 without inhibitory or induction effects
- Interactions
- Irbesartan (decreases aliskiren by 50%)
- Atorvastatin (increases aliskiren by 50%)
- Furosemide (Aliskaren decreases Furosemide efficacy by up to 50%)
- Ketoconazole (increases aliskiren by 80%)
- Monitoring: Check response 2 weeks after starting medication
- Serum Creatinine
- Serum electrolytes (esp. Serum Potassium)
- Blood Pressure response
- Efficacy
- Similar effect on Blood Pressure as ACE Inhibitors and Angiotensin Receptor Blockers
- Indications
- Dosing
- Start: 150 mg orally daily
- Maximum: 300 mg daily
- Adverse effects
- References
aliskiren (C1120110) | |
|---|---|
| Concepts | Organic Chemical (T109) , Pharmacologic Substance (T121) |
| MSH | C446481 |
| English | aliskiren |
| Parent Concepts | Antihypertensive Agents (C0003364), 1H-tetrazole (C0045089), Renin inhibitor (C1960108) |
| Sources | MSH, NCI, RXNORM, SNOMEDCT, VANDF Derived from the NIH UMLS (Unified Medical Language System) |
Tekturna (C1870961) | |
|---|---|
| Concepts | Organic Chemical (T109) , Pharmacologic Substance (T121) |
| MSH | C446481 |
| English | Tekturna |
| Sources | MSH, RXNORM Derived from the NIH UMLS (Unified Medical Language System) |
